Expand all sections

Ozenoxacine

Ozanex

Extended indication Kortetermijnbehandeling van niet-bulleuze impetigo bij volwassenen, adolescenten en kinderen vanaf 2
Therapeutic value No judgement

Product

Active substance Ozenoxacine
Domain Infectious diseases
Main indication Bacterial infections
Extended indication Kortetermijnbehandeling van niet-bulleuze impetigo bij volwassenen, adolescenten en kinderen vanaf 2 jaar.
Proprietary name Ozanex
Manufacturer cipher
Route of administration Cutaneous
Therapeutical formulation Cream
Budgetting framework Extramural (GVS)
Additional remarks Ozenoxacine is een antibioticumhoudende crème voor behandeling van impetigo (krentenbaard).

Registration

Registration route National (CBG)
Expected Registration 2018
Orphan drug No
Additional remarks Vervolgonderzoek gewenst door CBG naar het risico op de ontwikkeling van antibioticaresistentie per juli 2017.

Therapeutic value

Therapeutic value No judgement
Substantiation Geen meerwaarde verwacht.
Duration of treatment Average 5 day / days
Frequency of administration 2 times a day

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.